Medicine and Dentistry
Patient
100%
Cabazitaxel
87%
Docetaxel
50%
Toxicity
37%
Overall Survival
37%
Progression Free Survival
37%
Prostate Specific Antigen
37%
Castration Resistant Prostate Cancer
37%
Drug Megadose
25%
Low Drug Dose
25%
Survival Time
25%
Neutropenia
25%
Therapeutic Procedure
25%
Survival
25%
Adverse Event
12%
Hazard Ratio
12%
Prostate Cancer
12%
Hemoglobin
12%
Bone Metastasis
12%
Diagnosis
12%
Hospital
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cabazitaxel
87%
Docetaxel
50%
Toxicity
37%
Overall Survival
37%
Prostate Specific Antigen
37%
Progression Free Survival
37%
Castration Resistant Prostate Cancer
37%
Neutropenia
25%
Survival Time
25%
Survival
25%
Adverse Event
12%
Prostate Cancer
12%
Hemoglobin
12%
Bone Metastasis
12%
Biochemistry, Genetics and Molecular Biology
Dose
87%
Prostate-Specific Antigen
37%
Overall Survival
37%
Progression Free Survival
37%
Drug Megadose
25%
Low Drug Dose
25%
Survival Time
25%
Survival
25%
Hemoglobin
12%
Multivariate Analysis
12%
Bone
12%